Unraveling Malaria: A Comprehensive Review for Osteopathic Family Physicians

ABSTRACT

Malaria is a disease that has been known to humans for centuries.^1–4 It is caused by the Plasmodium protozoan parasite and transmitted through the bite of an infected female Anopheles mosquito.^5,6 Of the five species of Plasmodium, the deadliest is P. falciparum.^2,7–9 Malaria remains one of the world's most pressing public health problems, endemic in many parts of the world, particularly in sub-Saharan Africa and South Asia.^10,11 Malaria transmission occurs primarily in rural or peri-urban areas affected by climate and environmental factors.^12,13 A disease process often presenting with symptoms of fever, chills, sweats, headache, and muscle pain, malaria can vary depending on the species of the parasite involved and the individual's age, immunity status, and underlying health conditions.¹⁴ Diagnosing malaria is primarily based on clinical symptoms and laboratory tests. Direct microscopy is the gold standard for diagnosing malaria. Additionally, rapid diagnostic tests and polymerase chain reaction-based techniques play a crucial role in the diagnostic process.¹⁵ The prompt initiation of effective antimalarial treatment is critical for improving health outcomes and reducing the spread of infection. However, over the last century, Plasmodium has evolved leading to antimalarial drug resistance as a complicating factor.⁷ Nevertheless, preventing malaria is essential for reducing the morbidity and mortality associated with the disease.

Traditional approaches such as the use of insecticide-treated mosquito nets and indoor residual spraying continue to be employed in the battle against malaria.^16,17 Governmental funding and global initiatives have funded the necessary research for safe and successful antimalarial vaccines.^12,18 With continued efforts, the endemic regions of malaria are shrinking, and the eradication of malaria is becoming a more tangible reality.

INTRODUCTION

Malaria is a potentially life-threatening disease that affects millions of people globally, particularly in sub-Saharan Africa.^10,19 It is caused by the Plasmodium protozoan parasite and transmitted through the bite of an infected female Anopheles mosquito.⁵ Malaria poses a significant burden on public health systems worldwide, especially in endemic regions. Although significant progress has been made in the past decades, malaria remains a major cause of morbidity and mortality, particularly among children under 5 and pregnant women.^20–23 The World Health Organization (WHO) estimates that there were 247 million cases of malaria in 2021, resulting in an estimated 619,000 deaths globally.²⁴ Over half of all deaths reported globally occurred in four sub-Saharan African countries, Nigeria (31%), Democratic Republic of the Congo (13%), Niger (4%), and United Republic of Tanzania (4%).

Despite these alarming statistics, there has been much progress in controlling and decreasing malaria cases and mortality rates globally through various interventions, including insecticide- treated bed nets, indoor residual spraying, and antimalarial drugs. In this scientific review article, a comprehensive overview of malaria focuses on its epidemiology, pathophysiology, symptoms, diagnosis, treatment, and prevention. Having analyzed multiple academic sources to present the latest research findings on the topic, the goal is to increase awareness of malaria among family medicine physicians who play a critical role in the front-line management of malaria cases.

EPIDEMIOLOGY

Malaria, caused by the Plasmodium protozoan parasite, remains a major public health concern worldwide. Understanding the epidemiology of malaria is crucial for the design and implementation of effective prevention and control strategies. Malaria affects millions of people each year, predominantly in lower and middle-income countries, especially in sub-Saharan Africa.^9,18 According to the World Health Organization (WHO), an estimated 247 million cases and 619,000 deaths occurred in 2021.²⁴ Children under the age of 5 and pregnant women are particularly vulnerable to severe forms of the disease.²³ Malaria poses a significant socioeconomic burden, hindering development in affected regions.

Malaria is currently endemic in 84 countries as of 2021, mainly in tropical and subtropical regions.²⁴ Also, an estimated 95% of all malaria cases came from the WHO African Region, and the WHO South-East Asia Region accounted for only an estimated 2% of global malaria cases in 2021. Several factors influence the distribution of malaria, such as climate, geography, and human population movements. The disease is more prevalent in areas with high temperatures, humidity, and rainfall, which favor the growth of mosquito vectors. Factors like forest cover, irrigation projects, and urbanization also affect the distribution of malaria, leading to specific malaria hotspots.²⁵

Poverty, inadequate healthcare infrastructure, lack of access to preventive measures, and weak surveillance systems amplify malaria transmission.11 Environmental factors, such as deforestation and climate change, alter mosquito habitats and contribute to increased transmission rates.⁴ Socioeconomic and behavioral factors, such as poor housing conditions, limited education, and inadequate vector control measures, also play a significant role. Enhanced surveillance, research, and collaboration are imperative to tackle the challenges faced in malaria epidemiology and ensure sustained progress in combating this devastating disease.²⁴

PATHOPHYSIOLOGY

Understanding the pathophysiology of malaria is crucial in developing effective prevention strategies and devising appropriate treatment plans. Malaria is caused by the parasitic infection of the Plasmodium genus, with five species known to infect humans: P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi.^9,11,26 These parasites are transmitted to humans through the bites of infected female Anopheles mosquitoes.¹⁴

The pathophysiology of malaria begins with the injection of sporozoites, the infective form of the parasite, into the host's bloodstream.27–30 These sporozoites travel to the liver, where they invade hepatocytes.²⁷ Within the hepatocytes, the parasite undergoes asexual replication, resulting in the formation of thousands of merozoites.^27–29,31 This process ultimately leads to the rupture of infected hepatocytes, releasing merozoites into the bloodstream. Once released into the bloodstream, merozoites invade more red blood cells (RBCs). Within the RBCs, the parasites go through a complex life cycle involving repeated rounds of replication. The merozoites initially transform into ring- stage trophozoites, which subsequently mature into larger trophozoites and schizonts.²⁹ Eventually, these schizonts rupture the infected RBCs, releasing additional merozoites to invade new RBCs and perpetuate the infection cycle.^14,28

The intracellular growth and replication of Plasmodium parasites adversely affect the host's RBCs, leading to significant pathological consequences.^32,33 The destruction of RBCs in large numbers causes the characteristic periodic fevers associated with malaria.²⁸ This fever pattern reflects the synchronous release of merozoites from ruptured RBCs, resulting in cyclical bouts of high fever, followed by temporary relief during the intervals between parasite replication cycles. In severe cases of malaria, such as those caused by P. falciparum, infected RBCs may adhere to endothelial cells lining the blood vessels, leading to sequestration in various organs, including the brain.34–38 Such sequestration can cause blockages and impair the blood supply, resulting in organ dysfunction and potentially severe complications, including cerebral malaria.^{14,34,35,37,38}

Moreover, Plasmodium parasites have developed numerous mechanisms to evade the immune system, further contributing to the severity and chronicity of the infection.²⁸ The parasite modifies the surface of infected RBCs, making it difficult for the host's immune cells to recognize and destroy them effectively.³⁹ Additionally, Plasmodium antigens can induce an overactive immune response, leading to excessive inflammation and tissue damage.^28,38 Many of the complications associated with malaria are a result of an excessive host inflammatory response.⁴⁰ This response can lead to the release of inflammatory cytokines such as tumor necrosis factor a (TNF-a), causing endothelial dysfunction, disruption of the blood-brain barrier, and multi-organ dysfunction, among other complications.^28,38 The pathophysiology of malaria encompasses a complex interplay between the Plasmodium protozoan parasite and the host's immune system.¹⁴

SYMPTOMS

The clinical manifestations of malaria are diverse and can vary depending on several factors, including the species of Plasmodium involved, the patient's immune status, degree of prior exposure, and host genetic factors. In nonimmune patients, an asymptomatic malaria infection can swiftly negatively progress.41 While the symptoms may not be uniform for all cases, they generally fall into three categories: uncomplicated malaria, severe malaria, and subclinical malaria.

1. Uncomplicated Malaria

Uncomplicated malaria refers to symptomatic cases that do not exhibit severe or life- threatening complications.2,42 Moreover, patients who fall into this classification of malaria do not exhibit end-organ damage or vital organ failure.40 The classic symptoms typically include:

a) Fever: Fever is the most common symptom and often follows a cyclic pattern in which it rises and falls periodically.^7,28,43 In P. vivax and P. ovale malarial infections, the fever pattern is described as tertian as maturation of schizonts occurs every 48 hours.^1,44 Comparatively, a 72 hour fever pattern, or quartan fever, is observed in P. malariae infections due to its longer schizont maturation cycle.^1,44 However, irregular fever patterns can also occur, and this situation is evident in P. falciparum infections.

b) Chills and Sweating: Affected individuals commonly experience intense shivering and chills, followed by profuse sweating as the fever subsides.^7,43,44

c) Headache and Body Aches: Severe headaches and generalized body aches, including muscle and joint pain, are frequently observed.^7,38,43

d) Fatigue and Weakness: Malaria can cause severe fatigue and weakness, leading to a significant impact on daily activities.43,44 The inability to sit, or prostration, unassisted is often observed.²⁰

e) Gastrointestinal Disturbances: Nausea, vomiting, diarrhea, and abdominal discomfort may be present in some cases, along with a loss of appetite.^43,44

2. Severe Malaria

Severe malaria represents a medical emergency and requires immediate intervention.^20,42 This degree of complication is most often exhibited in P. falciparum and to a lesser degree in P. vivax and P. knowlesi.^{2,20,41,42,45,46} The patient having greater than 5% pigment-containing neutrophils or the occurrence of late-stage parasitemia is an indicator of negative outcomes.^41,42 Moreover, another indicator of poor outcome is seen in the presence of a large degree of parasitemia without correlating severe symptoms. Mortality rates can reach as high as 20% even in the context of appropriate therapy, and for pregnant patients, the mortality is near 50% according to some data.

Symptoms in severe cases include:

a) Impaired Consciousness: One of the defining characteristics of severe malaria is altered consciousness, ranging from confusion to coma.^20,38,42,43 Of note, coma is typically seen in P. falciparum infections and has not been linked to P. knowlesi thus far.⁴⁶ This can prove to be challenging for the clinician as the identification of parasitemia in endemic regions may be an incidental finding since many individuals in these regions develop malarial immunity over time. In fact, patients may be comatose for other reasons. Therefore, to confirm a malarial-induced coma, the presence of retinopathy should be identified.47 Specifically, the presence of focal changes in vessel color and patchy retinal whitening is an important diagnostic hallmark to delineate cerebral malaria from other encephalopathies.^20,38,47,48

b) Seizures: The occurrence of seizures in adults and particularly in children is a significant indicator of severe malaria and warrants immediate medical attention.^20,35,37,38

c) Organ Dysfunction: Severe malaria can lead to complications such as acute kidney injury, liver dysfunction, lung problems, and circulatory collapse.^20,42,43,46 Shock is a major complication that requires a prompt and aggressively appropriate degree of fluid resuscitation.²⁰ Pulmonary edema can lead to significant respiratory failure requiring intubation.²⁰ Liver failure can precipitate the appearance of jaundice.²⁰ Hypoglycemia may also be evident throughout the presentation.²⁰ Finally, acute kidney injury and acidosis may become exacerbated leading to various electrolyte abnormalities.²⁰

d) Anemia and Bleeding Disorders: Individuals with severe malaria may develop anemia due to the destruction of red blood cells.^2,20,37,42 Additionally, bleeding disorders, both internally and externally, may be observed in some cases.^20,43 This may include, albeit more rare, bleeding from the nose and gums.²⁰

Diagnosing malaria is a complex task that requires a multifaceted approach. While microscopy remains the gold standard, RDTs offer a reliable alternative in resource- limited settings^.52 Moreover, molecular techniques exhibit high sensitivity and specificity, although their implementation is often limited by cost and infrastructure requirements.^42,51 Ongoing advancements in imaging technologies and machine learning hold promise for more accurate and efficient malaria diagnosis in the future. Customizing diagnostic strategies based on local epidemiological factors and resource availability will be crucial for effective malaria control and elimination efforts worldwide.⁵²

TREATMENT

Since the 1940s, synthetic antimalarial drugs have been the cornerstone of malaria treatment.^9,43,45 These drugs primarily target the intraerythrocytic stages of the Plasmodium parasite, suppressing its replication and growth.²⁸ Quinoline derivatives are some of the oldest agents used in the treatment of malaria.^45,56 Quinine is an alkaloid extracted from the bark of Cinchona.^43,56 Chloroquine, for instance, engineered during World War II, was once considered the gold standard for uncomplicated malaria.^9,26,56–59 However, the emergence of drug resistance, as early as 15 years after the introduction of chloroquine in the 1950s, compromised its efficacy in various parts of the world, necessitating the development of alternative medications.^9,56,58,60

Antifolate antimalarial drugs have also been used since World War II.⁶¹ These agents fall into two subclasses – inhibitors of dihydropteroate synthase (DHPS) and inhibitors of dihydrofolate reductase (DHFR), class I and class II antifolates, respectively.61 Proguanil, first reported on in 1945, is a class I antifolate often used as a prophylactic antimalarial drug and more recently used in combination for a synergistic effect.⁶¹ The most potent class II antifolate is dapsone which was first synthesized in 1908.61 However, the antimalarial effects of dapsone were not known until the 1940s.⁵⁸

Artemisinins, derived from the Artemisia annua plant, are a group of highly effective antimalarial compounds that were first extracted in 1972.^9,56,60,62 One such medication in this group is Artesunate, an intravenous drug used in severe malarial infections.^{1,36,37,41,42} Artesunate eliminates circulating Plasmodium in the ring-stage capable of being cleared by the spleen which is a major limitation of quinine.⁶³ Artemisinin-based combination therapies (ACTs) have become the recommended first- line treatment for uncomplicated malaria in most endemic regions.^1,51,64 Combining artemisinins with other antimalarial drugs, such as lumefantrine or mefloquine, creates synergistic effects that enhance treatment efficacy.⁶⁴ ACTs have shown exceptional effectiveness in reducing parasite clearance time and preventing the emergence of drug resistance.

Despite the significant progress made in malaria treatment, several challenges persist. Drug resistance, particularly in Southeast Asia, poses a grave threat to the efficacy of both artemisinins and partner drugs.⁶⁴ Vigilant monitoring and surveillance systems are essential to detect and respond promptly to emerging resistance patterns. Another critical aspect is ensuring adequate adherence to treatment regimens, as incomplete courses contribute to the development of drug resistance and treatment failure.

Strategies such as directly observed therapy and community engagement programs are crucial to enhancing treatment compliance and minimizing the risk of transmission.³⁷

To overcome the challenges related to drug resistance, ongoing research is focused on novel antimalarial compounds with diverse mechanisms of action.^7,28,56 These include new classes of drug candidates, targets, and delivery mechanisms that may enhance treatment effectiveness and reduce the likelihood of resistance development.⁵⁶ Additionally, vaccines, such as RTS,S/AS01, have shown promise in preventing malaria infection and could potentially complement drug-based interventions in the future.^{1,12,18,28,36,65–67} However, the Plasmodium protozoan parasite genome compared to the genetic composition of bacteria and viruses is more intricate and multifaceted.¹⁸

PREVENTION

Malaria continues to be a significant public health concern, particularly in regions where the disease is endemic. With millions of new cases reported each year, effective prevention strategies are crucial in reducing the burden of this mosquito-borne illness.^1,28 The most effective approach in preventing malaria involves controlling the vector responsible for transmitting the disease – the female Anopheles mosquito.^1,2 Through the use of insecticide-treated mosquito nets (ITNs) and indoor residual spraying (IRS), mosquitoes can be repelled or killed, ultimately interrupting their life cycle and reducing the risk of transmission.^{1,4,16,17,20,28,59,68,69} There were 220 million ITNs sent to malaria endemic regions in 2021 by suppliers.²⁴ Moreover, it was reported that nearly 70% of households had a minimum of one ITNs in sub-Saharan Africa. However, as of 2021, the use of IRS in vulnerable areas decreased by 3.1% over the previous 11 year period. Nevertheless, both ITNs and IRS have demonstrated considerable success in reducing malaria incidence, particularly in high-risk areas.^1,4,16,28,70

Another critical component in malaria prevention is chemoprevention, which involves the use of antimalarial drugs to prevent infection or reduce disease severity.^28,44

Intermittent Preventive Treatment (IPT) is commonly used in pregnant women and infants at risk of malaria.⁶⁸ Additionally, chemoprophylaxis is recommended for individuals traveling to malaria-endemic regions.^28,44,71 Travelers may use chloroquine and hydroxychloroquine, with the latter regarded as having a better tolerance, when traveling to chloroquine-sensitive regions such as Mexico, Central America, and Hispaniola.⁴⁴ Primaquine is an option for P. vivax prevalent areas.⁴⁴ In chloroquine- resistant areas, such as South America, Asia, and Africa, doxycycline, atovaquone/proguanil, and mefloquine are the preferred prophylaxis choices.^9,44,60 A well-managed provision of antimalarial drugs can help prevent new infections and mitigate the impact of the disease on vulnerable populations.

Environmental management strategies focus on eliminating potential breeding grounds for mosquito vectors.⁷² This includes effective waste management, proper water drainage, and reducing standing water sources^.4,70 Community-based initiatives that raise awareness about the importance of environmental cleanliness and personal responsibility for preventing mosquito breeding sites have shown promising results.²² Integrated Vector Management (IVM) approaches encompass a comprehensive combination of vector control measures tailored to local settings and transmission dynamics.⁷³ This strategy involves coordinated efforts from multiple sectors, including health, agriculture, and public works, emphasizing community participation. By integrating various prevention techniques, such as ITNs, IRS, larval source management, and environmental modifications, IVM has the potential to considerably reduce malaria transmission rates.^4,16,20,72 Finally, vaccination efforts, coupled with other preventive interventions, can achieve better protection, thus enhancing overall malaria prevention strategies.

CONCLUSION

Malaria is a complex disease that can lead to various life-threatening complications affecting multiple organ systems. Prompt diagnosis, appropriate treatment, and supportive care are paramount in preventing or mitigating the severity of these complications. Nonetheless, the emergence of drug-resistant strains of malaria parasites demands continuous research and development of new therapeutic strategies to combat this global health burden effectively. By unraveling the intricate web of malaria-associated complications, scientists and healthcare professionals can subsequently devise more effective preventive measures and treatment interventions to reduce the devastating impact of this ancient disease worldwide.

REFERENCES

1. Nureye D, Assefa S. Old and Recent Advances in Life Cycle, Pathogenesis, Diagnosis, Prevention, and Treatment of Malaria Including Perspectives in Ethiopia. Sci World J. 2020;2020:1-17. doi:10.1155/2020/1295381
2. Shahbodaghi SD, Rathjen NA. Malaria: Prevention, Diagnosis, and Treatment. Am Fam Physician. 2022;106(3):270-278.
3. Talapko, Škrlec, Alebić, Jukić, Včev. Malaria: The Past and the Present. Microorganisms. 2019;7(6):179. doi:10.3390/microorganisms7060179
4. Nosten F, Richard-Lenoble D, Danis M. A brief history of malaria. Presse Médicale. 2022;51(3):104130. doi:10.1016/j.lpm.2022.104130
5. Daily JP, Minuti A, Khan N. Diagnosis, Treatment, and Prevention of Malaria in the US: A Review. JAMA. 2022;328(5):460-471. doi:10.1001/jama.2022.12366
6. Alho RM, Machado KVA, Val FFA, et al. Alternative Transmission Routes in the Malaria Elimination Era: An Overview of Transfusion-Transmitted Malaria in the Americas. Malar J. 2017;16(1):78. doi:10.1186/s12936-017-1726-y
7. Shibeshi MA, Kifle ZD, Atnafie SA. Antimalarial Drug Resistance and Novel Targets for Antimalarial Drug Discovery. Infect Drug Resist. 2020;13:4047-4060. doi:10.2147/IDR.S279433
8. Kapishnikov S, Staalsø T, Yang Y, et al. Mode of action of quinoline antimalarial drugs in red blood cells infected by Plasmodium falciparum revealed in vivo. Proc Natl Acad Sci. 2019;116(46):22946-22952. doi:10.1073/pnas.1910123116
9. Belete TM. Recent Progress in the Development of New Antimalarial Drugs with Novel Targets. Drug Des Devel Ther. 2020;14:3875-3889. doi:10.2147/DDDT.S265602
10. Johnson BA, Kalra MG. Prevention of Malaria in Travelers. Am Fam Physician. 2012;85(10):973-977.
11. Savi MK. An Overview of Malaria Transmission Mechanisms, Control, and Modeling. Med Sci Basel Switz. 2022;11(1):3. doi:10.3390/medsci11010003
12. Verma R, Khanna P, Chawla S. Malaria Vaccine Can Prevent Millions of Deaths in the World.

    Hum Vaccines Immunother. 2013;9(6):1268-1271. doi:10.4161/hv.23950

13. Briët OJT, Vounatsou P, Gunawardena DM, Galappaththy GNL, Amerasinghe PH. Temporal Correlation Between Malaria and Rainfall in Sri Lanka. Malar J. 2008;7:77. doi:10.1186/1475-2875-7-77
14. Marks M, Gupta-Wright A, Doherty JF, Singer M, Walker D. Managing Malaria in the Intensive Care Unit. Br J Anaesth. 2014;113(6):910-921. doi:10.1093/bja/aeu157
15. Maltha J, Gillet P, Jacobs J. Malaria rapid diagnostic tests in travel medicine. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2013;19(5):408-415. doi:10.1111/1469- 0691.12152
16. Tangena JAA, Hendriks CMJ, Devine M, et al. Indoor residual spraying for malaria control in sub-Saharan Africa 1997 to 2017: an adjusted retrospective analysis. Malar J. 2020;19(1):150. doi:10.1186/s12936-020-03216-6
17. Lindsay SW, Thomas MB, Kleinschmidt I. Threats to the effectiveness of insecticide-treated bednets for malaria control: thinking beyond insecticide resistance. Lancet Glob Health. 2021;9(9):e1325-e1331. doi:10.1016/S2214-109X(21)00216-3
18. Arora N, Anbalagan LC, Pannu AK. Towards Eradication of Malaria: Is the WHO’s RTS,S/AS01 Vaccination Effective Enough? Risk Manag Healthc Policy. 2021;Volume 14:1033-1039. doi:10.2147/RMHP.S219294
19. Brabin BJ. Malaria’s Contribution to World War One - The Unexpected Adversary. Malar J. 2014;13:497. doi:10.1186/1475-2875-13-497
20. World Health Organization. Severe Malaria. Trop Med Int Health. 2014;19:7-131. doi:10.1111/tmi.12313_2
21. Fowkes FJI, Boeuf P, Beeson JG. Immunity to Malaria in an Era of Declining Malaria Transmission. Parasitology. 2016;143(2):139-153. doi:10.1017/S0031182015001249
22. Sunguya BF, Mlunde LB, Ayer R, Jimba M. Towards eliminating malaria in high endemic countries: the roles of community health workers and related cadres and their challenges in integrated community case management for malaria: a systematic review. Malar J. 2017;16(1):10. doi:10.1186/s12936-016-1667-x
23. Dye-Braumuller KC, Kanyangarara M. Malaria in the USA: How Vulnerable Are We to Future Outbreaks? Curr Trop Med Rep. 2021;8(1):43-51. doi:10.1007/s40475-020-00224-z
24. World Health Organization. World Malaria Report 2022. World Health Organization; 2022. https://apps.who.int/iris/handle/10665/365169
25. Cotter C, Sturrock HJW, Hsiang MS, et al. The Changing Epidemiology of Malaria Elimination: New Strategies for New Challenges. Lancet Lond Engl. 2013;382(9895):900-911. doi:10.1016/S0140-6736(13)60310-4
26. Lover AA, Baird JK, Gosling R, Price RN. Malaria Elimination: Time to Target All Species. Am J Trop Med Hyg. 2018;99(1):17-23. doi:10.4269/ajtmh.17-0869
27. Bonam SR, Rénia L, Tadepalli G, Bayry J, Kumar HMS. Plasmodium falciparum Malaria Vaccines and Vaccine Adjuvants. Vaccines. 2021;9(10):1072. doi:10.3390/vaccines9101072
28. Fikadu M, Ashenafi E. Malaria: An Overview. Infect Drug Resist. 2023;Volume 16:3339-3347. doi:10.2147/IDR.S405668
29. Venugopal K, Hentzschel F, Valkiūnas G, Marti M. Plasmodium asexual growth and sexual development in the haematopoietic niche of the host. Nat Rev Microbiol. 2020;18(3):177-

    189. doi:10.1038/s41579-019-0306-2

30. Loubens M, Vincensini L, Fernandes P, Briquet S, Marinach C, Silvie O. Plasmodium sporozoites on the move: Switching from cell traversal to productive invasion of hepatocytes. Mol Microbiol. 2021;115(5):870-881. doi:10.1111/mmi.14645

31. Elaagip A, Absalon S, Florentin A. Apicoplast Dynamics During Plasmodium Cell Cycle. Front Cell Infect Microbiol. 2022;12:864819. doi:10.3389/fcimb.2022.864819
32. Zuccala ES, Baum J. Cytoskeletal and membrane remodelling during malaria parasite invasion of the human erythrocyte: Review. Br J Haematol. 2011;154(6):680-689. doi:10.1111/j.1365-2141.2011.08766.x
33. Kafai NM, Odom John AR. Malaria in Children. Infect Dis Clin North Am. 2018;32(1):189-200. doi:10.1016/j.idc.2017.10.008
34. Dunst J, Kamena F, Matuschewski K. Cytokines and Chemokines in Cerebral Malaria Pathogenesis. Front Cell Infect Microbiol. 2017;7:324. doi:10.3389/fcimb.2017.00324
35. Hawkes M, Elphinstone RE, Conroy AL, Kain KC. Contrasting pediatric and adult cerebral malaria: The role of the endothelial barrier. Virulence. 2013;4(6):543-555. doi:10.4161/viru.25949
36. Albrecht-Schgoer K, Lackner P, Schmutzhard E, Baier G. Cerebral Malaria: Current Clinical and Immunological Aspects. Front Immunol. 2022;13:863568. doi:10.3389/fimmu.2022.863568
37. Seydel KB, Kampondeni SD, Valim C, et al. Brain Swelling and Death in Children with Cerebral Malaria. N Engl J Med. 2015;372(12):1126-1137. doi:10.1056/NEJMoa1400116
38. Idro R, Jenkins NE, Newton CR. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol. 2005;4(12):827-840. doi:10.1016/S1474-4422(05)70247-7
39. Chen F, Flaherty BR, Cohen CE, Peterson DS, Zhao Y. Direct detection of malaria infected red blood cells by surface enhanced Raman spectroscopy. Nanomedicine Nanotechnol Biol Med. 2016;12(6):1445-1451. doi:10.1016/j.nano.2016.03.001
40. Milner DA. Malaria Pathogenesis. Cold Spring Harb Perspect Med. 2018;8(1):a025569. doi:10.1101/cshperspect.a025569
41. Plewes K, Leopold SJ, Kingston HWF, Dondorp AM. Malaria: What’s New in the Management of Malaria? Infect Dis Clin North Am. 2019;33(1):39-60. doi:10.1016/j.idc.2018.10.002
42. Global Health, Division of Parasitic Diseases and Malaria. Treatment of Malaria: Guidelines for Clinicians (United States). Centers for Disease Control and Prevention. Published June 28, 2023. Accessed September 4, 2023. https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html
43. Jensen M, Mehlhorn H. Seventy-five years of Resochin® in the fight against malaria.

    Parasitol Res. 2009;105(3):609-627. doi:10.1007/s00436-009-1524-8

44. Castelli F, Odolini S, Autino B, Foca E, Russo R. Malaria Prophylaxis: A Comprehensive Review. Pharmaceuticals. 2010;3(10):3212-3239. doi:10.3390/ph3103212
45. Pinheiro LCS, Feitosa LM, Silveira FFD, Boechat N. Current Antimalarial Therapies and Advances in the Development of Semi-Synthetic Artemisinin Derivatives. An Acad Bras Ciênc. 2018;90(1 suppl 2):1251-1271. doi:10.1590/0001-3765201820170830
46. Barber BE, Grigg MJ, Piera KA, et al. Intravascular haemolysis in severe Plasmodium knowlesi malaria: association with endothelial activation, microvascular dysfunction, and acute kidney injury. Emerg Microbes Infect. 2018;7(1):1-10. doi:10.1038/s41426-018-0105-2
47. Beare NA, Lewallen S, Taylor TE, Molyneux ME. Redefining cerebral malaria by including malaria retinopathy. Future Microbiol. 2011;6(3):349-355. doi:10.2217/fmb.11.3
48. Taylor TE. Caring for children with cerebral malaria: insights gleaned from 20 years on a research ward in Malawi. Trans R Soc Trop Med Hyg. 2009;103(1):S6-S10. doi:10.1016/j.trstmh.2008.10.049
49. Peto TJ, Tripura R, Lee SJ, et al. Association between Subclinical Malaria Infection and Inflammatory Host Response in a Pre-Elimination Setting. Luty AJF, ed. PLOS ONE. 2016;11(7):e0158656. doi:10.1371/journal.pone.0158656
50. Lindblade KA, Steinhardt L, Samuels A, Kachur SP, Slutsker L. The silent threat: asymptomatic parasitemia and malaria transmission. Expert Rev Anti Infect Ther. 2013;11(6):623-639. doi:10.1586/eri.13.45
51. Amir A, Cheong FW, De Silva JR, Lau YL. Diagnostic tools in childhood malaria. Parasit Vectors. 2018;11(1):53. doi:10.1186/s13071-018-2617-y
52. Krampa F, Aniweh Y, Awandare G, Kanyong P. Recent Progress in the Development of Diagnostic Tests for Malaria. Diagnostics. 2017;7(3):54. doi:10.3390/diagnostics7030054
53. Enane LA, Sullivan KV, Spyridakis E, Feemster KA. Clinical Impact of Malaria Rapid Diagnostic Testing at a US Children’s Hospital. J Pediatr Infect Dis Soc. 2020;9(3):298-304. doi:10.1093/jpids/piz022
54. Khoshmanesh A, Dixon MWA, Kenny S, Tilley L, McNaughton D, Wood BR. Detection and Quantification of Early-Stage Malaria Parasites in Laboratory Infected Erythrocytes by Attenuated Total Reflectance Infrared Spectroscopy and Multivariate Analysis. Anal Chem. 2014;86(9):4379-4386. doi:10.1021/ac500199x
55. Heraud P, Chatchawal P, Wongwattanakul M, et al. Infrared spectroscopy coupled to cloud- based data management as a tool to diagnose malaria: a pilot study in a malaria-endemic country. Malar J. 2019;18(1):348. doi:10.1186/s12936-019-2945-1
56. Tse EG, Korsik M, Todd MH. The past, present and future of anti-malarial medicines. Malar

    J. 2019;18(1):93. doi:10.1186/s12936-019-2724-z

57. Krafts K, Hempelmann E, Skórska-Stania A. From methylene blue to chloroquine: a brief review of the development of an antimalarial therapy. Parasitol Res. 2012;111(1):1-6. doi:10.1007/s00436-012-2886-x
58. Teixeira C, Vale N, Pérez B, Gomes A, Gomes JRB, Gomes P. “Recycling” Classical Drugs for Malaria. Chem Rev. 2014;114(22):11164-11220. doi:10.1021/cr500123g
59. Snow RW. Global malaria eradication and the importance of Plasmodium falciparum epidemiology in Africa. BMC Med. 2015;13(1):23. doi:10.1186/s12916-014-0254-7
60. Blasco B, Leroy D, Fidock DA. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nat Med. 2017;23(8):917-928. doi:10.1038/nm.4381
61. Nzila A. The past, present and future of antifolates in the treatment of Plasmodium falciparum infection. J Antimicrob Chemother. 2006;57(6):1043-1054. doi:10.1093/jac/dkl104
62. Woodrow CJ, Haynes RK, Krishna S. Artemisinins. Postgrad Med J. 2005;81(952):71-78. doi:10.1136/pgmj.2004.028399
63. South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. The Lancet. 2005;366(9487):717-725. doi:10.1016/S0140-6736(05)67176-0
64. Amelo W, Makonnen E. Efforts Made to Eliminate Drug-Resistant Malaria and Its Challenges. BioMed Res Int. 2021;2021:5539544. doi:10.1155/2021/5539544
65. Draper SJ, Sack BK, King CR, et al. Malaria Vaccines: Recent Advances and New Horizons. Cell Host Microbe. 2018;24(1):43-56. doi:10.1016/j.chom.2018.06.008
66. Alonso PL, O’Brien KL. A Malaria Vaccine for Africa - An Important Step in a Century-Long Quest. N Engl J Med. 2022;386(11):1005-1007. doi:10.1056/NEJMp2116591
67. Laurens MB. RTS,S/AS01 vaccine (MosquirixTM): an overview. Hum Vaccines Immunother. 2020;16(3):480-489. doi:10.1080/21645515.2019.1669415
68. Roman E, Andrejko K, Wolf K, et al. Determinants of uptake of intermittent preventive treatment during pregnancy: a review. Malar J. 2019;18(1):372. doi:10.1186/s12936-019- 3004-7
69. Banks SD, Murray N, Wilder-Smith A, Logan JG. Insecticide-Treated Clothes for the Control of Vector-Borne Diseases: A Review on Effectiveness and Safety. Med Vet Entomol. 2014;28 Suppl 1:14-25. doi:10.1111/mve.12068
70. Wilson ML, Krogstad DJ, Arinaitwe E, et al. Urban Malaria: Understanding its Epidemiology, Ecology, and Transmission Across Seven Diverse ICEMR Network Sites. Am J Trop Med Hyg. 2015;93(3_Suppl):110-123. doi:10.4269/ajtmh.14-0834
71. Sanford C, McConnell A, Osborn J. The Pretravel Consultation. Am Fam Physician. 2016;94(8):620-627.
72. Gachelin G, Garner P, Ferroni E, Verhave JP, Opinel A. Evidence and strategies for malaria prevention and control: a historical analysis. Malar J. 2018;17(1):96. doi:10.1186/s12936- 018-2244-2
73. Beier JC, Keating J, Githure JI, Macdonald MB, Impoinvil DE, Novak RJ. Integrated vector management for malaria control. Malar J. 2008;7(S1):S4. doi:10.1186/1475-2875-7-S1-S4